PL3758708T3 - Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid - Google Patents

Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid

Info

Publication number
PL3758708T3
PL3758708T3 PL19716296.9T PL19716296T PL3758708T3 PL 3758708 T3 PL3758708 T3 PL 3758708T3 PL 19716296 T PL19716296 T PL 19716296T PL 3758708 T3 PL3758708 T3 PL 3758708T3
Authority
PL
Poland
Prior art keywords
oxazepane
benzoxazol
carboxamide
dihydro
oxo
Prior art date
Application number
PL19716296.9T
Other languages
English (en)
Inventor
Håkan WIKSTRÖM
Jufang Wu LUDVIGSSON
Thomas Andersson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PL3758708T3 publication Critical patent/PL3758708T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19716296.9T 2018-03-01 2019-03-01 Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid PL3758708T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862636944P 2018-03-01 2018-03-01
PCT/EP2019/055138 WO2019166626A1 (en) 2018-03-01 2019-03-01 PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4-OXAZEPANE-2-CARBOXAMIDE

Publications (1)

Publication Number Publication Date
PL3758708T3 true PL3758708T3 (pl) 2025-03-31

Family

ID=66102025

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19716296.9T PL3758708T3 (pl) 2018-03-01 2019-03-01 Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid

Country Status (21)

Country Link
US (3) US12059424B2 (pl)
EP (2) EP3758708B1 (pl)
JP (3) JP7336450B2 (pl)
KR (2) KR102738945B1 (pl)
CN (3) CN118416078A (pl)
AU (3) AU2019228717C1 (pl)
CA (1) CA3091707A1 (pl)
DK (1) DK3758708T3 (pl)
ES (1) ES3011730T3 (pl)
FI (1) FI3758708T3 (pl)
HR (1) HRP20250115T1 (pl)
HU (1) HUE070049T2 (pl)
LT (1) LT3758708T (pl)
MA (1) MA52424B1 (pl)
MD (1) MD3758708T2 (pl)
PL (1) PL3758708T3 (pl)
PT (1) PT3758708T (pl)
RS (1) RS66494B1 (pl)
SI (1) SI3758708T1 (pl)
SM (1) SMT202500062T1 (pl)
WO (1) WO2019166626A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (pl) 2014-01-24 2018-02-24
KR20240091302A (ko) * 2016-07-29 2024-06-21 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
PL3758708T3 (pl) 2018-03-01 2025-03-31 Astrazeneca Ab Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
JP2023535332A (ja) 2020-07-20 2023-08-17 インスメッド インコーポレイテッド 好中球セリンプロテアーゼを抽出するおよびジペプチジルペプチダーゼ１媒介性病態を治療するための方法
JP7693817B2 (ja) * 2021-02-05 2025-06-17 エス－インフィニティ ファーマシューティカルズ カンパニー リミテッド １，４－オキサゼパンを含む縮合環誘導体
US20240226112A1 (en) * 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
CN115925696A (zh) * 2021-10-29 2023-04-07 瑞石生物医药有限公司 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途
EP4423071A4 (en) * 2021-10-29 2025-08-13 Insmed Inc USES OF CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINO-SINUSITIS
JP2025504817A (ja) * 2022-01-11 2025-02-19 上海壹典医▲薬▼科技▲開▼▲発▼有限公司 ペプチジルニトリル化合物及びその使用
EP4646265A1 (en) 2023-01-06 2025-11-12 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof
WO2024193695A1 (zh) * 2023-03-23 2024-09-26 西藏海思科制药有限公司 一种二肽基肽酶小分子抑制剂的药物组合物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6462076B2 (en) 2000-06-14 2002-10-08 Hoffmann-La Roche Inc. Beta-amino acid nitrile derivatives as cathepsin K inhibitors
US20110236367A1 (en) 2000-09-08 2011-09-29 Telenav, Inc. Rat cathespin dipeptidyl peptidase i (dppi): crystal structure and its uses
AU3815102A (en) 2000-09-08 2002-03-22 Prozymex As Dipeptidyl peptidase I crystal structure and its uses
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
BR0214642A (pt) 2001-12-04 2004-11-03 Hoffmann La Roche Compostos, métodos para a preparação de um composto, composições farmacêuticas que compreendem o mesmo e método para o tratamento e/ou prevenção de enfermidades que estão associadas com protéases de cisteìna e utilização desses compostos
US20040253311A1 (en) 2002-12-18 2004-12-16 Roger Berlin Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
WO2004076434A1 (en) 2003-02-28 2004-09-10 Aic Dipeptidyl peptidase inhibitors
CA2520124A1 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of benzazole compounds for immunopotentiation
US20070155803A1 (en) 2003-05-30 2007-07-05 Prozymex A/S Protease inhibitors
EP1638925A1 (en) 2003-06-18 2006-03-29 Prozymex A/S Protease inhibitors
EP1732949B1 (en) 2004-04-07 2010-01-27 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
EP1745292A2 (en) 2004-04-28 2007-01-24 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
US7618981B2 (en) 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
EP1916994B1 (en) 2004-06-29 2013-12-11 Takeda Pharma A/S Manufacturing of quick release pharmaceutical composition of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
WO2006020145A2 (en) 2004-07-19 2006-02-23 The Johns Hopkins University Flt3 inhibitors for immune suppression
CA3054535A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP2009500347A (ja) 2005-06-30 2009-01-08 アムジエン・インコーポレーテツド ビスアリールキナーゼ阻害剤及びこれらの炎症、血管新生及び癌の治療における使用
US20080221128A1 (en) 2007-03-07 2008-09-11 Christian Gege Metalloprotease inhibitors containing a squaramide moiety
TW200916447A (en) 2007-08-29 2009-04-16 Methylgene Inc Sirtuin inhibitors
MX2010003263A (es) 2007-09-25 2010-06-02 Novartis Ag Tratamiento de trastornos pulmonares con medicamentos aerosolizados tales como vancomicina.
US7902181B2 (en) 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
JP5752601B2 (ja) 2008-12-08 2015-07-22 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
US20100256194A1 (en) 2009-04-01 2010-10-07 Bial - Portela & Ca, S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
WO2010128324A1 (en) 2009-05-07 2010-11-11 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
ES3017582T3 (en) * 2010-04-07 2025-05-13 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
AU2013224421B2 (en) 2012-02-21 2017-03-02 Merck Patent Gmbh 8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors
CN104284895B (zh) 2012-04-17 2016-08-31 安斯泰来制药株式会社 含氮双环式芳香族杂环化合物
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
EP2775304A1 (en) 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
JP6441831B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．２］オクタン−３−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
EP2970283B1 (en) 2013-03-14 2020-11-11 Boehringer Ingelheim International GmbH Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
JP6441830B2 (ja) 2013-03-14 2018-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
JP6437929B2 (ja) 2013-03-14 2018-12-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2014165303A1 (en) 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
US10670594B2 (en) 2013-08-22 2020-06-02 Emory University Devices and methods related to airway inflammation
AU2014317048B2 (en) 2013-09-09 2018-05-10 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
WO2015032942A1 (en) 2013-09-09 2015-03-12 Prozymex A/S N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
NO2699580T3 (pl) 2014-01-24 2018-02-24
GB201402070D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
TW201622721A (zh) * 2014-04-10 2016-07-01 諾華公司 Ｓ１ｐ調節劑之立即釋放劑量療法
MX376012B (es) 2014-05-15 2025-03-07 Insmed Inc Metodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
WO2015180687A1 (en) 2014-05-30 2015-12-03 The University Of Hong Kong Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
JP6529575B2 (ja) 2014-08-01 2019-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
CN107074870B (zh) 2014-09-12 2019-07-12 勃林格殷格翰国际有限公司 组织蛋白酶c的螺环化合物抑制剂
EP3218372B1 (en) 2014-11-14 2020-05-20 Boehringer Ingelheim International GmbH Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
EP3265452B1 (en) 2015-03-05 2020-03-04 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
KR20240091302A (ko) 2016-07-29 2024-06-21 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
EP3749326A4 (en) 2018-02-07 2021-11-03 Insmed Incorporated CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
PL3758708T3 (pl) 2018-03-01 2025-03-31 Astrazeneca Ab Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
JP2021530513A (ja) 2018-07-17 2021-11-11 インスメッド インコーポレイテッド 炎症性腸疾患を処置するための特定の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニルエチル］−１，４−オキサゼパン−２−カルボキサミド
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
KR20230110821A (ko) 2019-04-17 2023-07-25 아조라 테라퓨틱스 인코포레이티드 염증성 피부 질환을 치료하기 위한 국소 조성물 및방법
BR112021024310A2 (pt) 2019-06-05 2022-02-15 Univ Emory Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
WO2022140516A1 (en) 2020-12-22 2022-06-30 Insmed Incorporated Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
CN112920124B (zh) 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
WO2022232420A1 (en) 2021-04-29 2022-11-03 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
US20240226112A1 (en) 2021-04-29 2024-07-11 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
EP4423071A4 (en) 2021-10-29 2025-08-13 Insmed Inc USES OF CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINO-SINUSITIS
AU2023221393A1 (en) 2022-02-16 2024-08-15 Insmed Incorporated Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

Also Published As

Publication number Publication date
US20240252512A1 (en) 2024-08-01
CN112055593B (zh) 2024-04-09
US20210369732A1 (en) 2021-12-02
JP2023156480A (ja) 2023-10-24
CN118416077A (zh) 2024-08-02
JP7336450B2 (ja) 2023-08-31
RS66494B1 (sr) 2025-03-31
HUE070049T2 (hu) 2025-05-28
LT3758708T (lt) 2025-02-25
MA52424B1 (fr) 2025-04-30
ES3011730T3 (en) 2025-04-08
CA3091707A1 (en) 2019-09-06
PT3758708T (pt) 2025-02-13
SMT202500062T1 (it) 2025-03-12
AU2019228717A1 (en) 2020-09-17
AU2019228717C1 (en) 2025-01-09
KR102738945B1 (ko) 2024-12-04
EP3758708B1 (en) 2024-11-27
US20250108060A1 (en) 2025-04-03
WO2019166626A1 (en) 2019-09-06
AU2024220121A1 (en) 2024-10-17
JP2025134766A (ja) 2025-09-17
MD3758708T2 (ro) 2025-04-30
AU2024220121B2 (en) 2026-03-26
DK3758708T3 (da) 2025-02-24
FI3758708T3 (fi) 2025-02-18
KR20210014621A (ko) 2021-02-09
AU2019228717B2 (en) 2024-07-04
CN112055593A (zh) 2020-12-08
EP4516353A2 (en) 2025-03-05
EP3758708A1 (en) 2021-01-06
US12059424B2 (en) 2024-08-13
AU2026201419A1 (en) 2026-03-19
KR20250002710A (ko) 2025-01-07
JP2021515006A (ja) 2021-06-17
US12201638B2 (en) 2025-01-21
SI3758708T1 (sl) 2025-04-30
HRP20250115T1 (hr) 2025-05-23
MA52424A (fr) 2021-01-06
CN118416078A (zh) 2024-08-02
EP4516353A3 (en) 2025-05-21

Similar Documents

Publication Publication Date Title
HUE070049T2 (hu) (2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények
IL279442A (en) Pharmaceutical preparations that include meloxicam
PL4072332T3 (pl) Wilgotne kompozycje doustne
IL275989B (en) Cannabinoid formulations are anesthetized for oral administration
GEP20237506B (en) Pcsk9 antagonist compounds
DK3805233T3 (da) (r)- og (s)-enantiomerer af n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazol-carboxamid som irak4-hæmmere til cancerbehandling
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
CL2013000685A1 (es) Compuestos derivados de n-(fenil/bencil)-6-(1,2,4-oxadiazol-3-il)-1,3,5-triazin-2,4-diamina; bloqueadores de los canales de sodio ( nav 1.7); composicion farmaceutica; que los comprende; uso en el tratamiento del dolor cronico.
DOP2010000326A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ZA201904002B (en) Oral care composition for long-lasting peroxide delivery
EP4043002A4 (en) Dental composition
BR112016019201A2 (pt) composições sólidas para os cuidados orais, método para a limpeza dos dentes e utilização de óxido de polietileno
BR112018004291A2 (pt) composição farmacêutica incluindo dutasterida e formulação de cápsula compreendendo a mesma
HUE059330T2 (hu) Toxinból származó bejuttatási konstrukciók orális beadásra
BR112017012646A2 (pt) Formas sólidas compreendendo (1e, 4e)-2-amino- n,n-dipropil-8-(4-(pirrolidina-1-carbonil) fenil)-3h- benzo[b]azepina-4-carboxamida, composições das mesmas, e uso das mesmas
EP3875088A4 (en) Package for medical composition containing anti-tumor agent
EP3796915A4 (en) ORAL FORMULATIONS CONTAINING RIVAROXABAN
IL285389A (en) Preparations containing meloxicam
BR112017001375A2 (pt) agente farmacêutico
CL2019003071A1 (es) Composiciones para el cuidado bucal.
EP3984549A4 (en) Medicinal composition
PL3845230T3 (pl) Kompozycja farmaceutyczna do podawania doustnego
IL250168A0 (en) Crystalline form of 5 – chloro –n ( { (5s) – 2 – oxo – 3 – [ 4 – ( 5,6 – dihydro – 4h – [ 1,2,4 ] triazin-1-yl) phenyl] – 1, 3-oxazolidine-5-yl}methyl)thiophene-2-an innovative carboxamide and pharmaceutical preparations containing it
ZA202101520B (en) Compound containing oxadiazole, and pharmaceutical composition containing same
HK40052027A (en) Pharmaceutical compositions comprising meloxicam